Planning For High-Performance Hematologic Oncology Clinical Trials

By Sari Heitner Enschede, MD, Senior Medical Director, Hematology-Medical Strategy Lead, Oncology Center of Excellence, IQVIA; and Christopher Morley, MPH, Senior Director, Hematology-Oncology Therapeutic Strategy Lead, IQVIA Biotech

Conducting successful clinical trials in hematologic malignancies demands a profound grasp of a swiftly advancing treatment landscape that is becoming progressively intricate, multifaceted, and individualized. Blood cancers present unique fundamental biology, clinical manifestations, and patient cohorts, mandating specialized clinical and operational proficiency to effectively orchestrate and execute trials evaluating innovative targeted interventions, notably cutting-edge cell and gene therapies.

Biotechnology firms must customize trial endpoints, methodologies, and data handling protocols, while also placing a premium on embracing the diversity of patient perspectives. This approach is essential for effectively navigating the intricacies and challenges inherent in investigating experimental agents for hematologic malignancies, a key focus of this study.